Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2023-08-24 Share Issue/Capital Cha…
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Share Issue/Capital Change 2023
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces an increase in share capital resulting from the exercise of employee warrants. This action directly relates to changes in the company's capital structure and share count. Based on the provided definitions, the 'Share Issue/Capital Change' (SHA) category is the most appropriate fit for documenting the issuance of new shares and the resulting change in total share capital. Although it involves employee compensation aspects, the primary focus and outcome reported is the capital increase itself.
2023-08-24 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive interim report for the six months ended June 30, 2023, for Zealand Pharma. It contains substantive financial data, including revenue, operating expenses, and cash position, as well as detailed management commentary on R&D, clinical trials, and future outlook. It is not merely an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-17 English
Zealand Pharma Announces Financial Results for the First Half of 2023
Interim / Quarterly Report Classification · 95% confidence The document is a formal 'Company announcement' from Zealand Pharma detailing their financial results for the first half of 2023. It includes key financial tables (Revenue, Net operating expenses, Cash position), management commentary, and operational highlights. While it is titled an 'interim report', it is presented as a company announcement/press release format containing the core financial data and analysis for the period, which fits the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-17 English
Earnings Release 2023
Earnings Release Classification · 100% confidence The document is titled "Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396" and is labeled as a "Company announcement – No. 27 / 2023". It details clinical trial results (safety, weight loss percentages) and discusses future development plans (Part 2 initiation). This content is characteristic of an initial release of periodic financial/operational results, focusing on key operational achievements (clinical trial success) rather than a comprehensive annual report (10-K) or a detailed management discussion (MDA). Since it announces specific, periodic results (clinical trial progress), it aligns best with the Earnings Release (ER) category, which often encompasses significant operational milestones for biotech/pharma companies, or potentially a Regulatory Filing (RNS) if it were purely a mandatory disclosure. Given the focus on positive results and forward-looking statements typical of an earnings-related announcement, ER is the most appropriate fit over the general RNS fallback. The document length (8783 chars) is substantial enough to be the primary announcement, not just a brief RPA. Q3 2023
2023-07-03 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short company announcement (2,783 characters) titled "Total number of shares and voting rights in Zealand Pharma at June 30, 2023". It explicitly states the total number of shares and voting rights as of a specific date, referencing compliance with the Danish Capital Markets Act. This type of mandatory disclosure regarding the total share count, often triggered by capital changes (like warrant exercises mentioned), is a regulatory filing. Since it is not a full annual report (10-K), an interim report (IR), or a specific transaction report (like DIRS or POS), and it is a direct regulatory disclosure, it fits best under the general 'Regulatory Filings' category (RNS) or potentially a specific capital/share change notification. Given the options, 'Major Shareholding Notification' (MRQ) is for changes in *ownership levels* by significant shareholders, not the total outstanding shares. 'Share Issue/Capital Change' (SHA) relates to the *action* of issuing shares. This document is a *report* of the resulting total share count. As a mandatory, periodic disclosure of share capital structure mandated by local law, RNS (Regulatory Filings) is the most appropriate general classification for this type of routine regulatory update that doesn't fit a more specific category like DIV or ER.
2023-06-30 English
Share Issue/Capital Change 2023
Share Issue/Capital Change Classification · 99% confidence The document is a company announcement titled "Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants." It explicitly details an increase in share capital due to the exercise of employee warrants, resulting in the issuance of 36,006 new shares and specifying the total proceeds. This action directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a simple announcement of a report (RPA).
2023-06-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.